Landmark vaccine approval offers new protection against dengue amid rising seasonal outbreaks nationwide.
In a landmark development for India’s public health system, the Drug Controller General of India (DCGI) has granted marketing authorisation to Japanese pharmaceutical company Takeda’s dengue vaccine, Qdenga (TAK003), making it the country’s first approved vaccine against dengue. Cleared for individuals aged 4 to 60 years, the vaccine is expected to significantly strengthen India’s efforts to reduce dengue-related illness, hospitalisations and deaths, especially as outbreaks continue to intensify during the monsoon season. Dengue remains one of India’s most persistent vector-borne diseases, with seasonal outbreaks placing enormous pressure on hospitals and public health infrastructure.
The approval of Qdenga provides an additional layer of protection alongside existing measures such as mosquito control, sanitation drives and public awareness campaigns. One of the vaccine’s biggest advantages is that it protects against all four dengue virus serotypes and does not require prior testing to determine whether an individual has previously been infected with dengue. This simplifies vaccination programmes and could enable broader community coverage once the vaccine becomes commercially available. The vaccine is administered in two doses, spaced three months apart. Public health experts believe the vaccine could substantially reduce the number of severe dengue cases that require hospitalisation. While no vaccine offers complete protection against infection, reducing disease severity can prevent complications such as dengue haemorrhagic fever and dengue shock syndrome, which account for most dengue-related fatalities.
Dr Neha Rastogi, an infectious disease specialist at a leading Delhi hospital, said the approval represents “an important milestone in preventive healthcare”. She noted that India has long relied almost entirely on mosquitocontrol measures and supportive treatment after infection. “A safe and effective vaccine introduces a preventive option that can reduce the overall disease burden, particularly in urban centres where dengue transmission is highest,” she said. Paediatricians also see major benefits for children, who are among the most vulnerable during annual outbreaks. Dr Rajiv Mehta, a senior paediatrician, said vaccination could help reduce school absenteeism, emergency admissions and the anxiety families face every monsoon. He added that preventing severe disease would also lessen the emotional and financial burden on households, many of which incur significant out-of-pocket expenses during dengue treatment. Experts, however, caution that vaccination should not lead to complacency.
Dr Shalini Kapoor, a community medicine expert, emphasised that mosquito control will continue to remain the cornerstone of dengue prevention. “Even after vaccination, eliminating mosquito breeding sites, using repellents, wearing protective clothing and ensuring proper sanitation are essential. Vaccination should complement, not replace, these preventive measures,” she observed. The approval also has broader implications for India’s healthcare system. During peak dengue seasons, hospitals often struggle with shortages of beds, platelets and critical care facilities. Fewer severe infections could reduce pressure on healthcare resources, allowing hospitals to better manage other seasonal illnesses. The vaccine’s introduction is also expected to benefit the economy indirectly. Dengue outbreaks result in lost workdays, reduced productivity and increased healthcare expenditure every year. By lowering the incidence of severe disease, vaccination could help reduce these economic losses while improving overall public health resilience. Health experts say the next challenge will be ensuring affordability and accessibility. Policymakers will need to determine whether the vaccine should eventually be incorporated into public immunisation programmes or initially remain available through the private healthcare sector. Its eventual uptake will depend on pricing, public awareness and recommendations from national immunisation authorities.
